Shorts

1:05
Aleece Fosnight, MSPAS, PA-C, on hormonally mediated bladder symptoms and IC/BPS
5 months ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES

1:05
Maxwell Sandberg, MD, outlines trial design for study evaluating treatment of RCC with a tumor thrombus
5 months ago
by
Maxwell L. Sandberg, MD

1:16
How an MMAI test can provide reassurance regarding prostate cancer treatment decisions
5 months ago
by
Daniel E. Spratt, MD

1:08
Jesse Mills, MD, on testosterone therapy and cardiovascular health
6 months ago
by
Jesse N. Mills, MD

1:03
Helen L. Bernie, DO, MPH, outlines how she evaluates hypogonadism
6 months ago
by
Helen L. Bernie, DO, MPH

1:04
Dean Elterman, MD, MSc, FRCSC, describes the efficiencies of the Zenflow system for BPH
6 months ago
by
Dean Elterman, MD, MSc

0:51
How the ProVee System for BPH preserves sexual function
6 months ago
by
Steven A. Kaplan, MD

0:57
Ilaha Isali, MD, MSc, on X chromosome biology and bladder cancer
6 months ago
by
Ilaha Isali, MD, MSc

1:13
Aleece Fosnight, MSPAS, PA-C, on why progesterone affects your bladder during your cycle
6 months ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES

1:04
Dean Elterman, MD, MSc, FRCSC, on the advantages of the nitinol-based Zenflow system
6 months ago
by
Dean Elterman, MD, MSc

1:21
Steven A. Kaplan, MD, on the ProVee System’s potential to replace medication for BPH
6 months ago
by
Steven A. Kaplan, MD

1:05
Raveen Syan, MD, FPMRS, on the Rising Star program at Urology on the Beach
6 months ago
by
Raveen Syan, MD, FPMRS

1:26
Mark L. Gonzalgo, MD, PhD, MBA, outlines what to expect from Urology on the Beach 2026
6 months ago
by
Mark L. Gonzalgo, MD, PhD, MBA

1:05
Steven Monda, MD, on germline variants in urothelial cancer
6 months ago
by
Steven Monda, MD

0:59
Mohit Khera, MD, MBA, MPH, on why TRT should not be a Schedule III controlled substance
6 months ago
by
Mohit Khera, MD, MBA, MPH

0:54
Jesse Mills, MD, on the effects of pairing anastrozole with TRT
6 months ago
by
Jesse N. Mills, MD

1:06
Aleece Fosnight, MSPAS, PA-C, on communication with patients with incontinence
6 months ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES

1:03
Pearls & Perspectives: Gaps in Care of Patients with Spinal Cord Injuries
6 months ago
by
Amy M. Pearlman, MD

0:44
Mark D. Tyson, II, MD, MPH, highlights topline data on cretostimogene in papillary NMIBC
6 months ago
by
Mark D. Tyson, II, M.D., M.P.H.

1:04
Sameena A. Rahman, MD, on the importance of countering misinformation on GSM
6 months ago
by
Sameena A. Rahman, MD

1:08
Alexandra Sokolova, MD, on how TRIPLE-SWITCH addresses a research gap in mCSPC
6 months ago
by
Alexandra Sokolova, MD

1:09
Timothy D. Lyon, MD, on the challenges of delivering BCG at home
6 months ago
by
Benjamin P. Saylor, Strategic Content Lead

1:16
Arvin George, MD, on what makes the Vanquish Water Vapor System unique
6 months ago
by
Arvin K. George, MD

1:25
Sameena A. Rahman, MD, on counseling patients with GSM
6 months ago
by
Sameena A. Rahman, MD

1:59
Leila Momtazi-Mar on role of testosterone and other factors in predicting sperm retrieval success
6 months ago
by
Leila Momtazi-Mar

1:16
Angela B. Smith, MD, MS, on proactively including PROs in bladder cancer trials
6 months ago
by
Angela B. Smith, MD, MS

1:01
Jesse Mills, MD, on why low T requires more than a single blood test
7 months ago
by
Jesse N. Mills, MD

0:52
Bogdana Schmidt, MD, MPH, shares why patients request nadofaragene re-induction
7 months ago
by
Bogdana Schmidt, MD, MPH

0:46
Aleece Fosnight, MSPAS, PA-C, on discussing incontinence with patients
7 months ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES

1:50
The truth behind this urology coding myth
7 months ago
by
Jonathan Rubenstein, MD
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5
